Made With Uberflip Content Marketing

BIO-Europe Spring 2017

The process of bringing a pharmaceutical drug to market once a lead compound has been identified: from drug discovery, funding, clinical trials, FDA approvals, and partnerships

  • BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs9:24

    BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

    Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa t

    Watch Video
  • BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets8:34

    BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets

    With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown bu

    Watch Video
  • BIO-Europe Spring® 2017:  Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies12:54

    BIO-Europe Spring® 2017: Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies

    By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an approach to treat necrotizing enterocolitis, a major killer of premature babies. Company CEO

    Watch Video
  • BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline9:39

    BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline

    Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strateg

    Watch Video
  • BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice8:16

    BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice

    Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transfor

    Watch Video
  • BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities10:02

    BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

    Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and

    Watch Video
  • BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment11:27

    BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

    Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors original

    Watch Video
  • Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    The buzz steadily grew as the Health Tech Competition got underway on the last day of BIO-Europe Spring® March 22 in Barcelona. As delegates filed into the competition room, the energy was...

    Read
  • BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations5:09

    BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

    Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i

    Watch Video
  • BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies8:22

    BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

    Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm

    Watch Video
  • BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech5:47

    BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech

    Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in startups and spinout biotech companies primarily in Europe. He spoke with Luke Timmerman, th

    Watch Video
  • BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition5:55

    BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition

    usMIMA is a team of scientists and engineers that has developed a solution for chronic constipation. The group won second place in BIO-Europe Spring's 2017 Healthtech Startup competition. MowoOT is fo

    Watch Video
  • BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones8:01

    BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

    Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clin

    Watch Video
  • BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development8:00

    BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development

    What kinds of partnerships are key to getting rare disease research out of the lab and to patients as therapies and cures? Wendy White, Board Chairman of Global Genes, discusses her work on behalf of

    Watch Video
  • BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs7:00

    BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

    During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug

    Watch Video
  • BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans6:13

    BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

    During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different

    Watch Video
  • BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy8:12

    BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

    As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's t

    Watch Video
  • BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations59:50

    BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations

    The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on the interactions between patients and their healthcare providers and between the healthcare

    Watch Video
  • BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe1:01:16

    BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe

    Europe is home to many of the biggest pharma companies and the best academic biomedical researchers. But the US is the dominant place with thriving hubs of biotech entrepreneurs, people taking big ris

    Watch Video
  • BIO-Europe Spring® 2017: Commercializing cell and gene therapies59:40

    BIO-Europe Spring® 2017: Commercializing cell and gene therapies

    New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

    Watch Video
  • loading
    Loading More...